Has Eli Lilly Stock Peaked?
Eli Lilly (LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first heal...
Here's why Eli Lilly stock is crashing
Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 revenue guidance, which fell short of Wall Street expectations.
Watch These Eli Lilly Price Levels as Stock Slumps on Tepid Sales Outlook
Eli Lilly (LLY) shares could remain under the microscope on Wednesday after falling sharply in trade on Tuesday as the pharmaceutical giant lowered its 2024 full-year revenue forecast.
Eli Lilly stumbles as weight-loss drug sales less than expected
Shares in Eli Lilly and Co fell 6.4% after the drugmaker said sales of its Mounjaro and Zepbound weight-loss medications grew more slowly than it had expected. CEO David Ricks said the US market f...
Eli Lilly lowers FY revenue forecast as weight loss drug sales fall short
Shares in Eli Lilly and Co (NYSE:LLY) fell 7.3% after the drugmaker said sales of its Mounjaro and Zepbound weight-loss medications grew more slowly than it had expected. CEO David Ricks said the U...
Eli Lilly CEO on prospect of insurance companies covering weight loss drugs
Eli Lilly CEO David Ricks discusses the potential of insurance companies covering weight loss drugs saying they will “recognize it's the ultimate prevention medication.”
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
Bad news for Eli Lilly (LLY -7.38%) stock dragged down shares of rival companies in the market for GLP-1 diet drugs on Tuesday. Lilly updated investors on its expected revenue for 2024 this morning...
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Shares dropped about 6%.
Mounjaro and Zepbound sales disappoint, and Eli Lilly's stock is dropping
Eli Lilly's stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and Zepbound missed expectations.
Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors
Eli Lilly (LLY) closed the most recent trading day at $797.48, moving -0.3% from the previous trading session.
Lilly sues two medical spas over copycat weight-loss drugs
Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound.
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?
Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.
LLY Falls Around 14% in 3 Months: How to Play the Stock
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Eli Lilly's obesity drug gets Medicare coverage for sleep apnea, CNBC reports
Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on Wednesday, citing the Centers for Medicare & Medicaid Services.
Related Companies